CAR-T治疗后淋巴细胞动力学与非霍奇金淋巴瘤预后
本研究分析复发/难治性弥漫大B细胞淋巴瘤患者接受CD19 CAR-T治疗后淋巴细胞增殖动力学对长期结局与毒性的影响。淋巴细胞早期增长符合指数函数,增殖速率是总生存的关键决定因素,阈值≥0.3876/天与更高完全缓解率和持久缓解相关,但细胞因子释放综合征等级更高。
要点
- 淋巴细胞增殖速率≥0.3876/天与更优完全缓解和持久缓解相关。
- 该阈值患者中位总生存3.04年,低于阈值者1.035年(p=0.0206)。
- 快速增殖者细胞因子释放综合征等级更高,需托珠单抗治疗。
核心结论
- 非霍奇金淋巴瘤CAR-T治疗后淋巴细胞扩增速度是缓解深度与持久性的主要决定因素。
研究设计与样本
- 研究分析弥漫大B细胞淋巴瘤患者接受淋巴清除化疗后CD19 CAR-T治疗的淋巴细胞增长动力学与长期结局及毒性。
主要发现
- CAR-T后早期淋巴细胞群体增长符合指数函数,细胞生长速率是总生存最关键决定因素之一。
- CAR-T后前4周淋巴细胞最大峰值和曲线下面积对生存无影响。
- 受试者工作特征分析确定增殖速率≥0.3876/天与更优完全缓解率和持久缓解率相关。
- 该阈值与更高级别细胞因子释放综合征及需托珠单抗相关。
- 该阈值患者中位总生存3.04年,较慢增殖者1.035年(p=0.0206)。
关键数值与推荐
- 淋巴细胞增殖速率阈值≥0.3876/天与更优完全缓解和持久缓解相关。
- 该阈值患者中位总生存3.04年,慢速增殖者1.035年(p=0.0206)。
临床怎么用
- 监测CAR-T后早期淋巴细胞增殖速率可能有助于识别缓解深度和持久性不同的患者。
- 快速淋巴细胞增殖患者需警惕更高等级细胞因子释放综合征及托珠单抗使用需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T cells directed against CD-19 are highly effective therapies for various subtypes of B-cell non-Hodgkin lymphoma (NHL). We have studied the impact of patient-specific lymphocyte growth kinetics after lymphoid depletion chemotherapy on both long-term outcomes and toxicity in patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL). The growth of the lymphocyte populations early after chimeric antigen receptor T-cell (CAR-T) therapy is well described by an exponential function and the growth rate of the cells appears to be one of the most critical determinants of overall survival in these patients. The maximum lymphocyte peak and the area under curve for lymphocytes within the first 4 weeks after CAR-T therapy had no impact on survival. Receiver operator characteristic analysis determined that a replication rate ≥0.3876/day is associated with superior rates of complete response and durable responses. This threshold is associated with higher grades of cytokine release syndrome and the need for tocilizumab. However, patients with this threshold have a median overall survival of 3.04 years compared to 1.035 years for patients with slower lymphocyte replication (p = 0.0206). The major determinant of depth of response and durability of response to CAR-T in NHL is the speed of lymphocyte expansion.
引用
- Dingli S, Rothweiler P, Corraes AMS, et al. Lymphocyte dynamics after CAR-T therapy for non-Hodgkin lymphoma. Br J Haematol. 2026. PMID: 42011548. doi:10.1111/bjh.70502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。